The global anticonvulsants market size was USD 18.16 Billion in 2021 and is expected to register a revenue CAGR of 2.3% during the forecast period, according to latest analysis by Emergen Research. Rising high-value investments in the healthcare sector along with increasing Research & Development (R&D) initiative by various major pharmaceutical companies for improvement in anticonvulsant therapy tolerability and drugs are major factors driving market revenue growth. In addition, rising incidences of epilepsy and various neurological disorders along with growing need for pain management caused by migraines are contributing to growth of the anticonvulsants market.
The report projects the market is anticipated to grow at a significant rate owing to raid advancements and technological developments in the sector. The report offers strategic recommendations to the businesses and investors to capitalize on the lucrative growth opportunities. The report further provides a comprehensive analysis of the competitive landscape and provides complete coverage with regard to company profiles, product portfolio, revenue generation, financial standing, and market position.
The leading market contenders listed in the report are:
GSK Group of Companies, Novartis AG, Pfizer Inc., UCB S.A, Johnson & Johnson Services, Inc., Abbott, Sunovion Pharmaceuticals Inc., Jazz Pharmaceuticals, Inc., Eisai Co., Ltd., and Sanofi.
The research study examines historic. The timeline makes the report an invaluable resource for readers, investors, and stakeholders looking for key insights in readily accessible documents with the information presented in the form of tables, charts, and graphs.
Market Overview:
The report bifurcates the Anticonvulsants market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.
Segments Covered in this report are:
Drug Type Outlook (Revenue, USD Billion; 2019-2030)
- α-Amino-3-Hydroxy-5-Methyl-4-isoxazole Propionic acid (AMPA)
- N-Methyl-D-Aspartate Receptor (NMDAR)
- Carbamate Anticonvulsants
- Barbiturate
- Carbonic Anhydrase Inhibitor
- Triazine
- Others
Drug Generation Outlook (Revenue, USD Billion; 2019-2030)
- First Generation
- Second Generation
- Third Generation
Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
The research report offers a comprehensive regional analysis of the market with regards to production and consumption patterns, import/export, market size and share in terms of volume and value, supply and demand dynamics, and presence of prominent players in each market.
Regional Analysis Covers:
North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Key reasons to buy the Global Anticonvulsants Market report:
- The latest report comprehensively studies the global Anticonvulsants market size and provides useful inference on numerous aspects of the market, such as the current business trends, market share, product offerings, and product share.
- The report offers an insightful analysis of the regional outlook of the market.
- It offers a detailed account of the end-use applications of the products & services offered by this industry.
- The report holistically covers the latest developments taking place in this industry. Therefore, it lists the most effective business strategies implemented by the market rivals for ideal business expansion.
No comments:
Post a Comment